Schwitzer seems to think so:
In today’s WSJ, the front page of the “Marketplace” section, page B1, has a story on the “blockbuster drug plavix” and a pack of new rivals on the horizon.
But negative findings on two other drug studies are relegated to pages B6 and B7, deep in the paper and deeper in that section.
